Scarica l'app Stockscreener
2.70
4.25%
0.11
Dopo l'orario di chiusura:
2.66
-0.04
-1.48%
Precedente Chiudi:
$2.59
Aprire:
$2.59
Volume 24 ore:
423.41K
Relative Volume:
0.29
Capitalizzazione di mercato:
$200.71M
Reddito:
$6.96M
Utile/perdita netta:
$-46.51M
Rapporto P/E:
-15.73
EPS:
-0.1716
Flusso di cassa netto:
$-37.99M
1 W Prestazione:
+11.11%
1M Prestazione:
-6.25%
6M Prestazione:
-33.50%
1 anno Prestazione:
-29.50%
Intervallo 1D:
$2.56
$2.70
Intervallo di 1 settimana:
$2.41
$2.78
Portata 52W:
$1.60
$5.3881
Perspective Therapeutics Inc Stock (CATX) Company Profile
Nome
Perspective Therapeutics Inc
Settore
Industria
Telefono
509-375-1202
Indirizzo
350 Hills Street, Suite 106, Richland
Confronta CATX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
2.70 | 192.54M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
108.27 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.61 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.57 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.69 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.60 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-10-10 | Iniziato | BTIG Research | Buy |
| 2025-03-13 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-11-25 | Downgrade | BofA Securities | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-01 | Iniziato | Wedbush | Outperform |
| 2024-09-25 | Iniziato | Truist | Buy |
| 2024-07-25 | Iniziato | BofA Securities | Buy |
| 2024-05-09 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Perspective Therapeutics Inc Borsa (CATX) Ultime notizie
Growth Report: Does Perspective Therapeutics Inc stock have upside surprise potential2025 Investor Takeaways & Short-Term Swing Trade Alerts - baoquankhu1.vn
Perspective Therapeutics (NYSEAMERICAN:CATX) Shares Down 4.4%Time to Sell? - MarketBeat
Can Perspective Therapeutics Inc expand into new marketsQuarterly Trade Review & Precise Buy Zone Identification - baoquankhu1.vn
Signal Recap: Whats the MACD signal for APLSPortfolio Performance Summary & Accurate Intraday Trading Signals - baoquankhu1.vn
Reviewing Perspective Therapeutics (NASDAQ:CATX) & CapsoVision (NASDAQ:CV) - Defense World
Analyzing Carlsmed (NASDAQ:CARL) and Perspective Therapeutics (NASDAQ:CATX) - Defense World
Aug Momentum: Is Perspective Therapeutics Inc part of any major indexRate Hike & Community Supported Trade Ideas - baoquankhu1.vn
CEO Moves: Is Perspective Therapeutics Inc part of any major indexMarket Performance Recap & Weekly Return Optimization Plans - baoquankhu1.vn
Critical Contrast: Perspective Therapeutics (NASDAQ:CATX) and Shoulder Innovations (NYSE:SI) - Defense World
Perspective Therapeutics, Inc Updates Corporate Presentation on Radiopharmaceuticals - TradingView — Track All Markets
Perspective Therapeutics (NASDAQ:CATX) Receives “Buy” Rating from BTIG Research - Defense World
BTIG Reiterates 'Buy' Rating for Perspective Therapeutics (CATX) with $14 PT | CATX Stock News - GuruFocus
Perspective Therapeutics' (CATX) Buy Rating Reiterated at BTIG Research - MarketBeat
Short Covering: Can Perspective Therapeutics Inc generate free cash flowEarnings Overview Summary & Consistent Growth Equity Picks - baoquankhu1.vn
Perspective Therapeutics outlines 2026 clinical and manufacturing priorities - TipRanks
Perspective Therapeutics Provides Business Updates and Strategic Priorities - TradingView
Perspective Therapeutics Provides Business Updates and - GlobeNewswire
How Perspective Therapeutics Inc. stock benefits from global expansionPerformance Line Overview & walk-ready comfort choices - Улправда
Perspective Therapeutics Reports Positive Interim Neuroendocrine Tumor Data - TipRanks
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium - The Manila Times
Experimental targeted radiation shows tumor shrinkage in early trial - Stock Titan
Will Perspective Therapeutics Inc. stock attract ESG investorsEarnings Recap Summary & Weekly High Potential Stock Alerts - Улправда
Why Perspective Therapeutics Inc. stock could see breakout soonQuarterly Earnings Report & Verified Swing Trading Watchlists - Улправда
Published on: 2026-01-08 23:03:38 - Улправда
Will Perspective Therapeutics Inc. stock continue upward momentum2025 Biggest Moves & Reliable Entry Point Alerts - Улправда
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX) and Foghorn Therapeutics (FHTX) - The Globe and Mail
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of “Buy” by Brokerages - Defense World
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Why Perspective Therapeutics Inc. stock remains a top recommendationFederal Reserve Announcements & Investor Community Interactions - bollywoodhelpline.com
Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Up 0.4%Should You Buy? - MarketBeat
Market Review: Will Perspective Therapeutics Inc stock continue upward momentumTrend Reversal & Risk Adjusted Buy and Sell Alerts - moha.gov.vn
Perspective Therapeutics (FRA:AAJ0) EV-to-OCF : -0.36 (As of Dec. 26, 2025) - GuruFocus
Aug Decliners: How Perspective Therapeutics Inc AAJ0 stock benefits from digital adoption2025 Stock Rankings & Daily Stock Trend Watchlist - moha.gov.vn
Perspective Therapeutics Inc Stock Analysis and ForecastRisk Management Strategies & Affordable Portfolio Tips - earlytimes.in
Can Perspective Therapeutics Inc. stock resist market sell offsWeekly Investment Recap & Weekly Momentum Picks - Улправда
Aug EndMonth: What market sentiment indicators show for Perspective Therapeutics Inc. (AAJ0) stockWeekly Profit Recap & Proven Capital Preservation Methods - Улправда
Perspective Therapeutics Earnings Notes - Trefis
How Perspective Therapeutics Inc. stock valuations compare to rivalsMarket Trend Review & Weekly Watchlist for Consistent Profits - Улправда
Published on: 2025-12-20 05:01:39 - Улправда
Market Review: What market sentiment indicators show for Perspective Therapeutics Inc. (AAJ0) stockQuarterly Growth Report & Low Risk High Win Rate Stock Picks - Улправда
Trading Recap: How Perspective Therapeutics Inc. stock valuations compare to rivals2025 Support & Resistance & AI Powered Market Trend Analysis - Улправда
Is Perspective Therapeutics Inc. stock in correction or buying zone2025 Fundamental Recap & Growth Focused Stock Reports - DonanımHaber
How Perspective Therapeutics Inc. (AAJ0) stock benefits from digital adoptionInsider Selling & Precise Trade Entry Recommendations - DonanımHaber
How Perspective Therapeutics Inc. stock compares to market leadersEarnings Growth Report & Community Supported Trade Ideas - DonanımHaber
Should I buy Perspective Therapeutics Inc. stock before earnings seasonJuly 2025 Spike Watch & Smart Investment Allocation Insights - Улправда
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Perspective Therapeutics, Inc. (CATX) 6.37% in After-hours: Stock Rises Amid Increased Investor Engagement - Stocks Telegraph
EV Market: How strong is Perspective Therapeutics Inc stock earnings growthTrade Signal Summary & Precise Buy Zone Identification - moha.gov.vn
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Average Rating of “Buy” from Brokerages - Defense World
Perspective Therapeutics Inc (CATX) Performance and Fundamentals Dashboard tells a completely different story - Setenews
Perspective Therapeutics Inc Azioni (CATX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.36%
0.96%
Capitalizzazione:
|
Volume (24 ore):